| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 13694 | 2012 |
| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 9566 | 2015 |
| Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6360 | 2015 |
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ... Nature 515 (7528), 563-567, 2014 | 5315 | 2014 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3543 | 2014 |
| First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ... New England Journal of Medicine 379 (23), 2220-2229, 2018 | 2693 | 2018 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2479 | 2017 |
| AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer PA Jänne, JCH Yang, DW Kim, D Planchard, Y Ohe, SS Ramalingam, ... New England Journal of Medicine 372 (18), 1689-1699, 2015 | 2267 | 2015 |
| Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 1929 | 2018 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1636 | 2015 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1283 | 2016 |
| Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ... Journal of clinical oncology 33 (18), 2004, 2015 | 1281 | 2015 |
| Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, J Bauman, LR Chirieac, ... Journal of the National Comprehensive Cancer Network 15 (4), 504-535, 2017 | 1181 | 2017 |
| Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ... Journal of Clinical Oncology 37 (28), 2518, 2019 | 1023 | 2019 |
| Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials … L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ... Journal of clinical oncology 35 (35), 3924, 2017 | 852 | 2017 |
| Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study S Gettinger, L Horn, D Jackman, D Spigel, S Antonia, M Hellmann, ... Journal of Clinical Oncology 36 (17), 1675-1684, 2018 | 686 | 2018 |
| NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines DS Ettinger, DE Wood, C Aggarwal, DL Aisner, W Akerley, JR Bauman, ... Journal of the National Comprehensive Cancer Network 17 (12), 1464-1472, 2019 | 667 | 2019 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 646 | 2020 |
| Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ... New England Journal of Medicine 383 (10), 931-943, 2020 | 638 | 2020 |
| First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992, 2019 | 536 | 2019 |
